surrogate endpoints - Robuta Search

https://data.mendeley.com/datasets/ytwp4wp3g6/1 Surrogate endpoints - dental caries - Mendeley Data Data used in "Is there an acceptable surrogate for caries clinical trials? Evidence from systematic reviews" surrogate endpoints dental caries mendeley data https://researchdiscovery.drexel.edu/esploro/outputs/journalArticle/Statistical-issues-for-HIV-surrogate-endpoints/991014878576104721 Statistical issues for HIV surrogate endpoints: point/counterpoint - Drexel University Nov 15, 1998 - Statistical issues for HIV surrogate endpoints: point/counterpoint - Drexel University - Journal article surrogate endpoints statistical issues hiv counterpoint https://fas.org/publication/validating-surrogate-endpoints/ Validating Surrogate Endpoints to Support FDA Drug Approval As surrogate markers are increasingly being accepted by FDA to support approval of new drugs and biologics, it is imperative that patients and clinicians... surrogate endpoints to support validating fda drug https://pharmagossip.blogspot.com/2009/10/gao-report-surrogate-endpoints-aint.html PharmaGossip: GAO Report - surrogate endpoints, ain't they a bitch! Highlights Full report. Before approving a drug, the Food and Drug Administration (FDA) assesses a drug's effectiveness. This assessment may... gao report surrogate endpoints bitch https://pmc.ncbi.nlm.nih.gov/articles/PMC5520356/ Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions,... Surrogate outcomes are not intrinsically beneficial to patients, but are designed to be easier and faster to measure than clinically meaningful outcomes. The... https://pmc.ncbi.nlm.nih.gov/articles/PMC7982798/ Value of Adaptive Trials and Surrogate Endpoints for Clinical Decision-Making in Rare Cancers - PMC Despite high-level endorsement, the number of adaptive Phase II/III trials in rare cancers needs to be improved, with better understanding of their value for... https://pubmed.ncbi.nlm.nih.gov/21298857/ [Two decades of statin trials: clinical, intermediate and surrogate endpoints] In the last 20 years clinical trials evaluating statins showed the importance of LDL-cholesterol lowering in decreasing the risk of cardiovascular disease. The... two decades statin trials clinical intermediate https://pubmed.ncbi.nlm.nih.gov/27857020/ Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A... Targeted agents investigated in the second-line treatment of mCRC provided minimal PFS gains translating into modest OS improvements. Considering both the...